Stock listing

NASDAQ:RADX Radiopharm Theranostics Limited Stock

US listing (NASDAQ) of Radiopharm Theranostics Limited · home listing ASX:RAD

Follow Radiopharm Theranostics Limited into a list and get an email when it puts out news.

Share price · NASDAQ:RADX

$0.63 USD -0.04 (-6.3%)

Close on Nov 20, 2026

Past year -78.6% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
$0.63 – $0.716 USDNov 20, 2026
Volume
12,982 sharesNov 20, 2026
Market cap
$9.20M USDAt the close on Nov 20, 2026 · price × 14.59M shares outstanding
52-week range
$0.63 – $16.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$95,021 USDMedian day 40,400 shares · last 3 months, Aug 20, 2026 – Nov 6, 2026
Radiopharm Theranostics Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:RAD · Home$0.0040 AUD+0.0010 (+33.3%)1,666,666$0.0030$0.0040$0.0030$0.0030Close on Nov 20, 2026
NASDAQ:RADX$0.63 USD-0.043 (-6.3%)12,982$0.716$0.716$0.63$0.673Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · NASDAQ:RADX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.959+0.07+7.9%$0.92$1.08$0.9079,200
$0.889+0.02+2.3%$0.904$0.99$0.83341,600
$0.869-0.021-2.4%$0.908$1.04$0.82369,500
$0.89-0.103-10.4%$0.945$0.96$0.8672,000
$0.993-0.087-8.1%$1.09$1.09$0.9738,300
$1.08-0.036-3.2%$1.09$1.161$1.088,900
$1.116+0.166+17.5%$0.98$1.12$0.95137,600
$0.95+0.05+5.6%$1.00$1.00$0.90125,100
$0.90-0.096-9.6%$0.95$0.951$0.9025,100
$0.996-0.014-1.4%$0.95$1.06$0.9517,300
$1.01+0.06+6.3%$1.074$1.074$0.99932,500
$0.95-0.029-3.0%$0.95$0.993$0.90515,800
$0.979-0.011-1.1%$0.96$1.01$0.9014,400
$0.99+0.027+2.8%$0.933$1.182$0.93331,400
$0.963-0.067-6.5%$1.01$1.14$0.96312,900
$1.03-0.05-4.6%$1.02$1.14$0.90106,400
$1.08-0.04-3.6%$1.12$1.15$1.01165,900
$1.12-0.08-6.7%$1.17$1.191$1.1139,200
$1.20+0.09+8.1%$1.07$1.33$1.01143,100
$1.11-0.02-1.8%$1.10$1.33$1.109,600
$1.13+0.02+1.8%$1.10$1.24$1.0665,800
$1.11-0.04-3.5%$1.13$1.156$1.0626,700
$1.15-0.03-2.5%$1.18$1.19$1.1042,400
$1.18-0.09-7.1%$1.28$1.28$1.1677,500
$1.27-0.15-10.6%$1.39$1.40$1.0082,300
$1.42-0.06-4.1%$1.44$1.65$1.4062,300
$1.48-0.14-8.6%$1.48$1.55$1.4048,000
$1.62+0.10+6.6%$1.60$1.63$1.4363,400
$1.520.000.0%$1.54$1.60$1.4742,900
$1.52-0.13-7.9%$1.60$1.80$1.5244,000
$1.65+0.078+5.0%$1.57$1.68$1.44137,600
$1.572-0.053-3.3%$1.61$1.68$1.48559,900
$1.625-0.025-1.5%$1.65$1.69$1.4935,700
$1.65+0.04+2.5%$1.69$1.69$1.5033,400
$1.61-0.04-2.4%$1.73$1.75$1.6036,000
$1.65-0.08-4.6%$1.74$1.842$1.6536,800
$1.73+0.06+3.6%$1.70$1.91$1.7066,500
$1.67+0.15+9.9%$1.56$1.80$1.55187,800
$1.52-0.49-24.4%$2.00$2.00$1.50163,300
$2.01+0.03+1.5%$2.01$2.075$1.9758,500
$1.98-0.08-3.9%$2.06$2.088$1.9837,600
$2.06-0.02-1.0%$2.11$2.28$2.0522,000
$2.08-0.04-1.9%$2.15$2.47$2.0573,800
$2.12+0.04+1.9%$2.08$2.297$2.0627,700
$2.08-0.075-3.5%$2.05$2.145$2.057,900
$2.155-0.005-0.2%$2.06$2.23$2.0518,700
$2.16-0.11-4.8%$2.27$2.30$2.0511,000
$2.27-0.01-0.4%$2.27$2.27$2.1814,600
$2.28-0.13-5.4%$2.37$2.442$2.18548,700
$2.41+0.15+6.6%$2.46$2.722$2.27333,300
$2.26-0.06-2.6%$2.18$2.327$2.044106,800
$2.32-0.16-6.5%$2.427$2.53$2.3218,600
$2.48+0.04+1.6%$2.42$2.537$2.3434,852
$2.440.000.0%$2.43$2.52$2.3573,074
$2.44+0.15+6.6%$2.355$2.522$2.3048,800
$2.29-0.21-8.4%$2.45$2.45$2.2388,900
Ticker
NASDAQ:RADX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Radiopharm Theranostics Limited news

Radiopharm Theranostics Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
76 in the last 12 months · 168 in all · newest Nov 15, 2026 · oldest 2021
Decks
28 decks · latest October 2026

Where Radiopharm Theranostics Limited is listed

ListingExchangeCountryCurrency
ASX:RAD · Home listingASXAustraliaAUD
NASDAQ:RADX · This pageNASDAQUnited StatesUSD
OTC:RDPTFOTCUnited StatesUSD
BOATS:RADXBOATSUnited StatesUSD

Valuation

EV/sales 4.8× against a median of 26.5×: 3rd lowest of 6 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$13.37M AUD
P/E
Loss
EV/sales
4.8×
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
−77.7%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Radiopharm Theranostics Limited · ASX:RADUS$11.59MUS$8.85Mn/a4.8×n/a0.7×n/a0.0×n/a
Xintela AB · OMXSTO:XINTUS$11.89MUS$11.82Mn/a39.8×n/an/an/an/an/a
BioCardia, Inc. · NASDAQ:BCDAUS$11.88MUS$10.22Mn/an/an/a14.2×n/a0.7×0.42
Pluri Inc. · NASDAQ:PLURUS$11.85MUS$38.65Mn/a26.5×n/an/an/an/a0.53
Synlogic Inc · OTC:SYBXUS$11.76MUS$201,442n/an/an/a1.2×n/a0.0×0.50
Imugene Ltd · ASX:IMUUS$11.74MUS$14.16Mn/an/an/a2.0×n/a0.7×n/a
Simris Group AB Class B · OMXSTO:SIMRIS_BUS$11.55MUS$19.55Mn/a144×n/a154×n/a117×n/a
Aelis Farma SA · EURONEXT:AELISUS$11.55MUS$9.09Mn/a4.0×n/a4.5×−308.7%1.9×n/a
Dyadic International, Inc. · NASDAQ:DYAIUS$11.51MUS$12.03Mn/a3.9×n/an/a−226.9%n/a1.12
Psyence Biomedical Ltd. · NASDAQ:PBMUS$11.33MUS$4.18Mn/an/an/a0.9×n/a0.0×0.90
Medicenna Therapeutics Corp. · TSX:MDNAUS$11.26MUS$7.37Mn/an/an/a9.7×n/a0.1×1.36
Median of the othersUS$11.64MUS$11.02M26.5×4.5×−267.8%0.7×0.72

Forecasts

Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
0.15 AUD · Analysts' mean
EPS, year to Jun 2027
-0.014 · 1 analyst
Revenue, year to Jun 2027
1.06M · 5 analysts

Team and board

Officers

OfficerRole
Riccardo CanevariManaging Director and CEO
Barbara LaniVP Quality Affairs
Donna SupkoVP Regulatory Affairs
Emily Love-LeonVP Clinical Operations
Levente MeszarosVP Preclinical and Translational Science
Melissa ThomasVP Portfolio Program Lead
Sherin Al-SafadiVP Medical and Corporate Affairs
Vimal PatelVP CMC
Dimitris VoliotisChief Medical Officer
Hitesh GoelHead of Project Management
Paul HopperExecutive Chairman

Board

DirectorRole
Paul HopperExecutive Chairman
Hester LarkinNon - Executive Director
Ian TurnerNon - Executive Director
Noel DonnellyNon Executive Director

Events

QuarterResultsShare move
Quarter to Mar 31, 2026Jun 3, 2026−9.5%
Q2 2026Feb 26, 2026+4.5%
Quarter to Sep 30, 2025Dec 3, 2025−4.5%
Q4 2025Sep 16, 2025+9.7%
Quarter to Mar 31, 2025May 28, 2025−8.0%
Q2 2025Feb 28, 2025 · Before open0.0%
Q1 2025Nov 27, 2024+7.1%
Q4 2024Aug 29, 2024+12.1%
Q3 2024Apr 15, 2024 · Before open−2.1%
Q2 2024Feb 29, 2024 · Before open+16.1%
All 17 quarters
QuarterResultsShare move
Q1 2024Nov 29, 2023+2.8%
Q4 2023Aug 30, 2023 · After close0.0%
Q3 2023May 31, 2023−3.6%
Q2 2023Feb 28, 2023 · Before open−3.7%
Q1 2023Nov 30, 2022+4.5%
Q4 2022Aug 30, 2022 · After close−8.6%
Q2 2022Feb 27, 2022 · After close−2.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck38 slidesOctober 2026
Investor Presentation (July 2026)Investor deck31 slidesJul 24, 2026
Investor Presentation (June 2026)Investor deck41 slidesJune 2026
Investor Presentation (December 2025)Investor deck60 slidesDecember 2025
Shareholder Meeting (November 2025)Shareholder meeting22 slidesNov 20, 2025
Investor Presentation (November 2025)Investor deck60 slidesNov 1, 2025
Investor Presentation (October 2025)Investor deck54 slidesOct 20, 2025
Corporate Update (October 2025)Corporate update43 slidesOct 20, 2025
Investor Presentation (August 2025)Investor deck61 slidesAugust 2025
Shareholder Meeting (November 2024)Shareholder meeting12 slidesNov 25, 2024
All 28 decks
DeckKindSlidesDate
Shareholder Meeting (August 2024)Shareholder meeting10 slidesAugust 2024
Investor Presentation (June 2024)Investor deck50 slidesJun 25, 2024
Oncology/Cell Tx Innovation: The Texas Trifecta (April 2024)Conference26 slidesApr 22, 2024
Shareholder Meeting (April 2024)Shareholder meeting8 slidesApr 15, 2024
B. Riley Securities Radiopharma Investor Conference 2024Conference16 slidesMar 4, 2024
Investor Presentation (January 2024)Investor deck23 slidesJan 24, 2024
Shareholder Meeting (November 2023)Shareholder meeting16 slidesNov 16, 2023
Bell Potter Healthcare Conference 2023Conference25 slidesNov 15, 2023
Investor Presentation (October 2023)Investor deck29 slidesOct 31, 2023
Shareholder Meeting (August 2023)Shareholder meeting7 slidesAug 18, 2023
Shareholder Meeting (November 2022)Shareholder meeting16 slidesNov 16, 2022
Joint Meeting of EORTC, NCI and AACR 2022Conference8 slidesOct 28, 2022
Investor Presentation (October 2022)Investor deck32 slidesOct 19, 2022
Investor Presentation (June 2022)Investor deck15 slidesJun 9, 2022
Bioshares Biotech Summit 2022Conference19 slidesMay 12, 2022
Investor Presentation (April 2022)Investor deck18 slidesApr 4, 2022
Investor Presentation (March 2022)Investor deck13 slidesMar 28, 2022
Investor Presentation (November 2021)Investor deck26 slidesNov 29, 2021

Open Decks

Financings

RaiseDateIn US dollars
Share purchase plan of sPP Shares with SPP Attaching Options
Closed: A$3M raised · A$0.009 a share · Warrants at A$0.018
Buyers: Trading Capital Management (HK) Ltd (~A$1.5 million pursuant to a shortfall commitment)
Insiders: ~A$0.1 million subscribed by participating Directors
Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes
Sep 17, 2026US$2.13M
Registered direct offering of american Depositary Shares with unregistered warrants
Announced: about US$4.1M · US$3.16 a share · Warrants at US$3.79 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes
Jul 27, 2026
Private placement of ordinary shares with attaching options
Announced: about A$6.7M · Warrants at A$0.018
Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes
Jul 27, 2026US$4.68M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021
Revenue2.77M3.63M299.2K292.4K8.83K0
Cost of revenue4.92M3.59M2.98M
Gross profit-2.15M39.3K299.2K292.4K-2.97M
Research and development50.0M27.5M23.1M22.6M7.49M
Selling, general and administrative18.6M12.4M300.6K
Operating income-68.3M-38.2M-47.2M-34.5M-19.9M-484.8K
Depreciation and amortization7.33K2.60M3.13M3.30M2.98M1.16M
EBITDA-68.3M-35.6M-44.1M-31.2M-16.9M678.7K
Interest expense112.4K65.3K642.9K86.1K9.35M0
Income before tax-56.9M-38.2M-47.9M-34.6M-30.3M-485.2K
Income tax-54.4K103.3K96.4K38.0K44.4K-1.16M
Net income-55.1M-38.3M-47.9M-34.6M-30.3M-485.2K
Earnings per share, basic-0.02-1.76-12.41-11.32-0.11-0.00
Earnings per share, diluted-1.76-12.41-11.32

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021
Cash and equivalents4.14M29.1M18.6M11.7M27.0M27.1K
Receivables17.4M10.4M987.4K4.47M56.5K6.35K
Inventory1-6.35K
Current assets21.9M39.9M22.8M27.3M33.4K
Property, plant and equipment53.5K60.8K1.58K
Total assets60.1M86.5M72.0M83.4M33.4K
Accounts payable5.47M9.34M10.9M5.12M1.19M64.4K
Current liabilities18.9M14.9M17.6M7.88M158.1K
Total debt59.0K
Total liabilities37.8M43.6M44.7M20.4M158.1K
Shareholders' equity24.7M42.9M27.4M45.6M63.0M-124.7K
Shares outstanding3.54B279.8M277.5M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021
Cash from operations-52.8M-36.6M-23.0M-23.2M-9.91M-32.9K
Capital spending-52.8M-45.3K-28.3M-1
Free cash flow-52.8M-23.2M-38.2M-32.9K
Cash from investing-5.42M1.77M-320.0K-1.53M-28.4M-28.4M
Cash from financing33.4M45.4M30.2M9.22M65.1M60.0K
Share buybacks-4.83M1.00K
Change in cash-25.0M10.6M6.90M-15.5M27.0M27.1K

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 16, 2026Current reportSEC
RAD interim analysis at SNO26 on RAD101 Phase IIb dataNov 15, 2026Other filingsASX
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerNov 12, 2026Current reportSEC
Change of Director's Interest Notices x 4Nov 10, 2026Ownership change noticeASX
6-K · Report of a foreign issuerNov 4, 2026Current reportSEC
RAD Alignment with US FDA for Development of RAD101Nov 3, 2026Other filingsASX
6-K · Report of a foreign issuerOct 30, 2026Current reportSEC
Quarterly Activities/Appendix 4C Cash Flow ReportOct 30, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 30, 2026Quarterly reportASX
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 27, 2026Insider tradeSEC
6-K · Report of a foreign issuerOct 27, 2026Current reportSEC
Notice of Annual General Meeting/Proxy FormOct 26, 2026Meeting noticeASX
6-K · Report of a foreign issuerOct 26, 2026Current reportSEC
Radiopharm receives $8M advance on FY26 R&D tax incentiveOct 26, 2026Other filingsASX
6-K · Report of a foreign issuerOct 20, 2026Current reportSEC
Notification regarding unquoted securities - RADOct 20, 2026Other filingsASX
Change of Director's Interest Notices x 4Oct 20, 2026Ownership change noticeASX
Notification of cessation of securities - RADOct 20, 2026FinancingASX
SCHEDULE 13G · Big-stake noticeOct 14, 2026Big-stake noticeSEC
Non-Compliance with Listing Rule 10.11Oct 11, 2026Legal or regulatory actionASX
6-K · Report of a foreign issuerOct 5, 2026Current reportSEC
RAD Completes Meeting with US FDA for Development of RAD101Oct 4, 2026Other filingsASX
6-K · Report of a foreign issuerOct 1, 2026Current reportSEC
Notification of cessation of securities - RADOct 1, 2026FinancingASX
Change of Director's Interest Notice (RC)Oct 1, 2026Ownership change noticeASX
20-F · Annual reportSep 30, 2026Annual reportSEC
6-K · Report of a foreign issuerSep 30, 2026Current reportSEC
Appendix 4G and Corporate Governance StatementSep 30, 2026Other filingsASX
Annual Report and Form 20-FSep 30, 2026Annual reportASX
EFFECT · Notice that a registration is effectiveSep 24, 2026Other filingsSEC
424B3 · ProspectusSep 23, 2026Offer documentSEC
6-K · Report of a foreign issuerSep 22, 2026Current reportSEC
Change of Director's Interest Notices x 4Sep 22, 2026Ownership change noticeASX
Notification regarding unquoted securities - RADSep 16, 2026Other filingsASX
RADOC New Class Options Range of Units and Top 20 HoldersSep 16, 2026Securities holder registration reportASX
Application for quotation of securities - RADSep 16, 2026FinancingASX
Application for quotation of securities - RADSep 16, 2026FinancingASX
Share purchase plan completedSep 16, 2026FinancingASX
6-K · Report of a foreign issuerSep 14, 2026Current reportSEC
F-3 · Registration statementSep 14, 2026Offer documentSEC
RAD oral presentation at SNO26 on RAD101 Phase IIb dataSep 13, 2026Other filingsASX
6-K · Report of a foreign issuerSep 11, 2026Current reportSEC
Results of MeetingSep 10, 2026Meeting outcomeASX
6-K · Report of a foreign issuerSep 9, 2026Current reportSEC
RAD Announces Positive Data from RAD301 P1 Imaging TrialSep 8, 2026Other filingsASX
SCHEDULE 13G · Big-stake noticeSep 4, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeSep 4, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerAug 28, 2026Current reportSEC
Appendix 4E and Preliminary Final ReportAug 28, 2026ResultsASX
6-K · Report of a foreign issuerAug 27, 2026Current reportSEC
Change of Director's Interest Notices x 4Aug 27, 2026Ownership change noticeASX
6-K · Report of a foreign issuerAug 26, 2026Current reportSEC
RAD Doses First Patient in Second Cohort of BetaBart (RV-01)Aug 25, 2026Other filingsASX
Ceasing to be a substantial holderAug 24, 2026Ownership change noticeASX
6-K · Report of a foreign issuerAug 20, 2026Current reportSEC
RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT TrialAug 19, 2026Other filingsASX
6-K · Report of a foreign issuerAug 17, 2026Current reportSEC
Change in substantial holdingAug 17, 2026Ownership change noticeASX
RAD to meet with US FDA to align on RAD 101 Phase 3 TrialAug 16, 2026Other filingsASX
6-K · Report of a foreign issuerAug 13, 2026Current reportSEC
Notice of Extraordinary General Meeting and Proxy FormAug 12, 2026Proxy formASX
Share Purchase Plan - Now OpenAug 6, 2026FinancingASX
Update - Proposed issue of securities - RADAug 4, 2026FinancingASX
6-K · Report of a foreign issuerAug 3, 2026Current reportSEC
Application for quotation of securities - RADAug 2, 2026FinancingASX
6-K · Report of a foreign issuerJul 31, 2026Current reportSEC
Quarterly Activities/Appendix 4C Cash Flow ReportJul 30, 2026Quarterly reportASX
Change in substantial holdingJul 30, 2026Ownership change noticeASX
Target market determination (TMD)Jul 30, 2026Other filingsASX
ProspectusJul 30, 2026Offer documentASX
6-K · Report of a foreign issuerJul 28, 2026Current reportSEC
6-K · Report of a foreign issuerJul 28, 2026Current reportSEC
Notice Under Section 708AJul 28, 2026Other filingsASX
Application for quotation of securities - RADJul 27, 2026FinancingASX
6-K · Report of a foreign issuerJul 27, 2026Current reportSEC
424B5 · ProspectusJul 27, 2026Offer documentSEC
6-K · Report of a foreign issuerJul 24, 2026Current reportSEC
RAD completes A$12.5 M placement and launches A$6 M SPPJul 24, 2026FinancingASX
424B5 · ProspectusJul 23, 2026Offer documentSEC
6-K · Report of a foreign issuerJul 22, 2026Current reportSEC
RAD Achieves Partial Response in Phase 1 Trial of RAD204Jul 21, 2026ResultsASX
6-K · Report of a foreign issuerJul 6, 2026Current reportSEC
6-K · Report of a foreign issuerJun 30, 2026Current reportSEC
6-K · Report of a foreign issuerJun 3, 2026Current reportSEC
3 · Initial statement of ownershipMay 6, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 6, 2026Insider tradeSEC
6-K · Report of a foreign issuerMay 1, 2026Current reportSEC
3 · Initial statement of ownershipApr 30, 2026Insider tradeSEC
6-K · Report of a foreign issuerApr 23, 2026Current reportSEC
6-K · Report of a foreign issuerApr 20, 2026Current reportSEC
6-K · Report of a foreign issuerApr 16, 2026Current reportSEC
RAD Completes Enrollment in Phase 2b Trial of RAD 101Apr 15, 2026Operations updateASX
6-K · Report of a foreign issuerApr 8, 2026Current reportSEC
RAD202 Phase 1 HEAT Trial Advances to Dose Level 3Apr 7, 2026Other filingsASX
6-K · Report of a foreign issuerApr 7, 2026Current reportSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 27, 2026Current reportSEC
RAD Doses First Patient in RAD 402 Phase 1 Clinical StudyMar 26, 2026Operations updateASX
6-K · Report of a foreign issuerMar 24, 2026Current reportSEC
RAD101 2nd interim Ph.2b data - 90% achieve primary endpointMar 23, 2026ResultsASX
6-K · Report of a foreign issuerMar 19, 2026Current reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerFeb 27, 2026Current reportSEC
Half Year Report and Appendix 4D 31 December 2025Feb 27, 2026Interim reportASX
6-K · Report of a foreign issuerFeb 24, 2026Current reportSEC
RAD Doses First Patient in 177Lu-BetaBart (RV-01) StudyFeb 23, 2026Operations updateASX
6-K · Report of a foreign issuerJan 28, 2026Current reportSEC
Quarterly Activities/Appendix 4C Cash Flow ReportJan 27, 2026Quarterly reportASX
SCHEDULE 13G/A · Big-stake notice, amendedJan 16, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerJan 12, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 8, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveDec 29, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveDec 29, 2025Other filingsSEC
424B3 · ProspectusDec 23, 2025Offer documentSEC
424B5 · ProspectusDec 23, 2025Offer documentSEC
CORRESP · Letter to the SECDec 19, 2025Other filingsSEC
CORRESP · Letter to the SECDec 19, 2025Other filingsSEC
6-K · Report of a foreign issuerDec 19, 2025Current reportSEC
F-3 · Registration statementDec 17, 2025Offer documentSEC
F-3 · Registration statementDec 16, 2025Offer documentSEC
6-K · Report of a foreign issuerDec 15, 2025Current reportSEC
RAD101 interim Phase 2b data - 92% achieve primary endpointDec 14, 2025Other filingsASX
20-F/A · Annual report, amendedDec 10, 2025Annual reportSEC
6-K · Report of a foreign issuerDec 3, 2025Current reportSEC
6-K · Report of a foreign issuerNov 25, 2025Current reportSEC
6-K · Report of a foreign issuerNov 20, 2025Current reportSEC
6-K · Report of a foreign issuerNov 19, 2025Current reportSEC
6-K · Report of a foreign issuerNov 18, 2025Current reportSEC
RAD Approval for Phase 1 Therapeutic Trial of RAD 402Nov 17, 2025Other filingsASX
6-K · Report of a foreign issuerNov 17, 2025Current reportSEC
RAD Announces 50% Enrollment in Phase 2b Trial of RAD101Nov 16, 2025Other filingsASX
6-K · Report of a foreign issuerNov 12, 2025Current reportSEC
RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204Nov 11, 2025Operations updateASX
6-K · Report of a foreign issuerNov 4, 2025Current reportSEC
6-K · Report of a foreign issuerNov 3, 2025Current reportSEC
6-K · Report of a foreign issuerOct 28, 2025Current reportSEC
6-K · Report of a foreign issuerOct 22, 2025Current reportSEC
6-K · Report of a foreign issuerOct 20, 2025Current reportSEC
ProspectusOct 20, 2025Offer documentASX
RAD completes A$35 M Placement and launches A$5 M SPPOct 19, 2025FinancingASX
Trading HaltOct 15, 2025Trading halt or suspensionASX
6-K · Report of a foreign issuerOct 7, 2025Current reportSEC
6-K · Report of a foreign issuerOct 1, 2025Current reportSEC
Radiopharm received approval for RAD 202 trial accelerationSep 30, 2025Other filingsASX
SPL:Research & Option Agreement with Radiopharm TheranosticsSep 30, 2025Other filingsASX
6-K · Report of a foreign issuerSep 29, 2025Current reportSEC
20-F · Annual reportSep 17, 2025Annual reportSEC
6-K · Report of a foreign issuerSep 17, 2025Current reportSEC
6-K · Report of a foreign issuerSep 15, 2025Current reportSEC
6-K · Report of a foreign issuerAug 29, 2025Current reportSEC
Appendix 4E and Preliminary Final ReportAug 29, 2025ResultsASX
6-K · Report of a foreign issuerAug 21, 2025Current reportSEC
6-K · Report of a foreign issuerAug 1, 2025Current reportSEC
6-K · Report of a foreign issuerJul 29, 2025Current reportSEC
6-K · Report of a foreign issuerJul 28, 2025Current reportSEC
RAD receives IND approval from US FDA for Betabart (RV-01)Jul 27, 2025Other filingsASX
SCHEDULE 13G · Big-stake noticeJul 23, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJul 21, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJul 16, 2025Current reportSEC
6-K · Report of a foreign issuerJun 23, 2025Current reportSEC
6-K · Report of a foreign issuerJun 12, 2025Current reportSEC
RAD Granted US FDA Fast Track for RAD101 Metastases ImagingJun 10, 2025Other filingsASX
6-K · Report of a foreign issuerJun 10, 2025Current reportSEC
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202Jun 3, 2025Other filingsASX
6-K · Report of a foreign issuerJun 3, 2025Current reportSEC
6-K · Report of a foreign issuerJun 2, 2025Current reportSEC
RAD Reports Positive Preclinical Lu177-B7H3-mAb DataJun 1, 2025Operations updateASX
6-K · Report of a foreign issuerMay 30, 2025Current reportSEC
6-K · Report of a foreign issuerMay 19, 2025Current reportSEC
6-K · Report of a foreign issuerMay 12, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2025Big-stake noticeSEC
Acceleration of RAD204 Phase 1 dose escalation trialMay 11, 2025Other filingsASX
6-K · Report of a foreign issuerApr 29, 2025Current reportSEC
6-K · Report of a foreign issuerApr 28, 2025Current reportSEC
First patient dosed in Phase IIb imaging for Brain MetsApr 27, 2025Operations updateASX
6-K · Report of a foreign issuerMar 17, 2025Current reportSEC
New RAD202 data confirms positive tumor uptakeMar 16, 2025Other filingsASX
6-K · Report of a foreign issuerMar 13, 2025Current reportSEC
6-K · Report of a foreign issuerMar 7, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 28, 2025Current reportSEC
Half Year Report and Appendix 4D 31 December 2024Feb 28, 2025Interim reportASX
6-K · Report of a foreign issuerFeb 25, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 24, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 10, 2025Current reportSEC
Clinical trial data shows RAD 101 detects Brain MetastasesFeb 9, 2025Other filingsASX
6-K · Report of a foreign issuerJan 30, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 29, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJan 21, 2025Current reportSEC
6-K · Report of a foreign issuerJan 10, 2025Current reportSEC
Lantheus increases shareholding in RAD with A$8m placementJan 9, 2025FinancingASX
6-K · Report of a foreign issuerDec 30, 2024Current reportSEC
Strategic Co-Development Partnership with Lantheus for AusDec 29, 2024Other filingsASX
6-K · Report of a foreign issuerDec 20, 2024Current reportSEC

This page holds 200 of 290 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Radiopharm Theranostics Limited’s releases · as of Sep 17, 2026

Common shares
4,377,549,491
Fully diluted
4,377,549,491

Fully diluted

LineShares
Common shares4,377,549,491

Warrants and options

Lot
Warrants · A$0.018 · expiry not stated

Share count over time

CountShares
Nov 22, 20264,377,549,491

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Armistice Capital, LLC450KUS$729KSep 30, 2026
Marex Group Ltd58,153US$94,208Sep 30, 2026
PNC Financial Services Group, Inc.50,000US$81,000Sep 30, 2026
Regal Partners Ltd39,976US$64,761Sep 30, 2026
HSBC22,483US$33,949Sep 30, 2026
UBS883US$1,430Sep 30, 2026
Quent Capital, LLC229US$371Sep 30, 2026
Rhumbline Advisers195US$315Sep 30, 2026

Big stakes

StakeStakeSharesDateFiling
Regal Partners Holdings Pty Limited9.05%321MDec 31, 2025Schedule 13G
Morgan Stanley5.60%273MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Aaron Laurita
Other companies: Immuron Limited (Chief Financial Officer · Since at least Feb 9, 2026)
Chief Financial Officer · Since at least Mar 18, 2026
Dimitris Voliotis
Other companies: Zentalis Pharmaceuticals, Inc. (SVP, Clinical Development · Apr 3, 2020 – Feb 10, 2022 · Past)
Chief Medical Officer · Since at least Mar 18, 2026
Noel Donnelly
Other companies: PepGen Inc. (Chief Financial Officer · Since at least May 5, 2022)
Director · Since at least Mar 18, 2026
Barbara LaniVP Quality Affairs · Since at least Nov 5, 2026
Bruce Michael GoodwinDirector · Since at least Mar 18, 2026
Donna SupkoVP Regulatory Affairs · Since at least Nov 4, 2026
Emily Love-LeonVP Clinical Operations · Since at least Nov 4, 2026
Hester LarkinNon - Executive Director · Since at least Mar 18, 2026
Hitesh GoelHead of Project Management · Since at least Nov 5, 2026
Ian TurnerNon - Executive Director · Since at least Mar 18, 2026
All 17 people
PersonSeat
John M. ViglottiSVP Corporate Services · Nov 5, 2025 – Nov 5, 2026 · Past
Levente MeszarosVP Preclinical and Translational Science · Since at least Nov 5, 2026
Melissa ThomasVP Portfolio Program Lead · Since at least Nov 5, 2026
Paul HopperExecutive Chairman · Since at least Mar 18, 2026
Riccardo CanevariManaging Director and CEO · Since at least Mar 18, 2026
Sherin Al-SafadiVP Medical and Corporate Affairs · Since at least Nov 5, 2026
Vimal PatelVP CMC · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Radiopharm Theranostics Limited.